ATE515261T1 - Zusammensetzungen zur behandlung von diabetes - Google Patents

Zusammensetzungen zur behandlung von diabetes

Info

Publication number
ATE515261T1
ATE515261T1 AT04815013T AT04815013T ATE515261T1 AT E515261 T1 ATE515261 T1 AT E515261T1 AT 04815013 T AT04815013 T AT 04815013T AT 04815013 T AT04815013 T AT 04815013T AT E515261 T1 ATE515261 T1 AT E515261T1
Authority
AT
Austria
Prior art keywords
compositions
treating diabetes
diabetes
treating
Prior art date
Application number
AT04815013T
Other languages
English (en)
Inventor
Piu Chan
Gary Kwan Po Wong
Jinxian Xu
Francis Chi
Original Assignee
Omega Bio Pharma Ip3 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Omega Bio Pharma Ip3 Ltd filed Critical Omega Bio Pharma Ip3 Ltd
Application granted granted Critical
Publication of ATE515261T1 publication Critical patent/ATE515261T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
AT04815013T 2003-12-19 2004-12-20 Zusammensetzungen zur behandlung von diabetes ATE515261T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53111903P 2003-12-19 2003-12-19
US59170904P 2004-07-27 2004-07-27
PCT/US2004/042884 WO2005063226A1 (en) 2003-12-19 2004-12-20 Compositions and methods for treating diabetes

Publications (1)

Publication Number Publication Date
ATE515261T1 true ATE515261T1 (de) 2011-07-15

Family

ID=34742984

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04815013T ATE515261T1 (de) 2003-12-19 2004-12-20 Zusammensetzungen zur behandlung von diabetes

Country Status (17)

Country Link
US (2) US7442720B2 (de)
EP (1) EP1696897B1 (de)
JP (1) JP4845740B2 (de)
KR (1) KR101329369B1 (de)
CN (1) CN101897970A (de)
AR (1) AR047779A1 (de)
AT (1) ATE515261T1 (de)
AU (1) AU2004308934B2 (de)
BR (1) BRPI0417829A (de)
CA (1) CA2549717C (de)
IL (1) IL176259A (de)
MX (1) MXPA06007100A (de)
MY (1) MY143799A (de)
RU (1) RU2367423C2 (de)
SG (1) SG149814A1 (de)
TW (1) TWI350751B (de)
WO (1) WO2005063226A1 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US9060941B2 (en) 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US7785627B2 (en) 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
WO2005049002A1 (en) 2003-11-19 2005-06-02 Omega Bio-Pharma International Ltd. Materials and methods for improving alcohol metabolism and alleviating the effects of hangovers
RU2367423C2 (ru) * 2003-12-19 2009-09-20 ОМЕГА БИО-ФАРМА (Ай.Пи. 3) ЛИМИТЕД Композиции и способы для лечения диабета
WO2005060342A2 (en) * 2003-12-19 2005-07-07 Omega Bio-Pharma International Ltd. Cysteamine compounds for treating allergy
EP1706104A2 (de) * 2004-01-13 2006-10-04 Omega Bio-Pharma (I.P.2) Limited Verfahren zur behandlung von stress und einflussnahme auf biologische immunsysteme unter verwendung einer cysteaminverbindung
CN1976691B (zh) * 2004-05-03 2010-10-13 奥加生物药业(I.P.3)有限公司 半胱胺用于治疗高胆固醇血症和糖尿病并发症
ATE409468T1 (de) * 2004-06-30 2008-10-15 Walcom Animal Science I P 3 Lt Materialien und verfahren zur verbesserung der gesundheit, der immunität und des wachstums bei schalentieren
US20070172514A1 (en) * 2006-01-20 2007-07-26 Francis Chi Materials and methods for improving livestock productivity
ES2388310T7 (es) * 2006-01-27 2017-05-03 The Regents Of The University Of California Cisteamina con recubrimiento entérico, cistamina y derivados de las mismas
AU2013267044B2 (en) * 2006-01-27 2016-07-07 The Regents Of The University Of California Enterically coated cysteamine, cystamine and derivatives thereof
US8138227B2 (en) * 2006-07-06 2012-03-20 Trustees Of Dartmouth College Method for inhibiting or reversing non-enzymatic glycation
US7993687B2 (en) 2006-07-12 2011-08-09 Julianne Marie Kawa Compositions and methods for management of diabetes
AR067557A1 (es) * 2007-07-19 2009-10-14 Takeda Pharmaceutical Preparacion solida y metodo de preparacion
WO2009070781A1 (en) 2007-11-30 2009-06-04 The Regents Of The University Of California Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine products
BR112012026219B1 (pt) * 2010-04-13 2019-12-10 M Lab Ag método para o diagnóstico de glaucoma, elementos carreadores de antígeno e kit
US8815562B2 (en) 2010-04-15 2014-08-26 The Regenys of the University of Michigan Biosynthetic pathway for heterologous expression of a nonribosomal peptide synthetase drug and analogs
GB201021186D0 (en) 2010-12-14 2011-01-26 Novabiotics Ltd Composition
LT2661266T (lt) 2011-01-07 2020-12-10 Anji Pharma (Us) Llc Gydimo būdai chemosensorinio receptoriaus ligando pagrindu
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
US8796338B2 (en) 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
US9572784B2 (en) 2011-01-07 2017-02-21 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
US9480663B2 (en) * 2011-01-07 2016-11-01 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
EP2670427A1 (de) * 2011-02-02 2013-12-11 Sanofi-Aventis Deutschland GmbH Vorbeugung von hypoglykämie bei patienten mit diabetes mellitus typ 2
JP6411215B2 (ja) * 2011-11-22 2018-10-24 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 虚血傷害を治療するためのシステアミンおよび／またはシスタミン
CN104254325A (zh) 2012-01-06 2014-12-31 埃尔舍利克斯治疗公司 双胍组合物和治疗代谢性病症的方法
CN110693867A (zh) 2012-01-06 2020-01-17 埃尔舍利克斯治疗公司 用于治疗代谢性病症的组合物和方法
US20140314841A1 (en) 2013-04-19 2014-10-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Use of Cysteamine and Derivatives Thereof to Suppress Tumor Metastases
AR096628A1 (es) 2013-06-17 2016-01-20 Raptor Pharmaceuticals Inc Formulación en perlas de cisteamina de liberación retardada y métodos de preparación y uso de ella
WO2015015403A2 (en) * 2013-08-01 2015-02-05 Mahesh Kandula Compositions and methods for the treatment of diabetes and pre-diabetes
JP2017527614A (ja) * 2014-09-02 2017-09-21 ブピンダー シン 重水素化又は非重水素化分子及び医薬製剤
GB201416716D0 (en) * 2014-09-22 2014-11-05 Novabiotics Ltd Use
CN108289867A (zh) 2015-07-02 2018-07-17 地平线孤儿病有限责任公司 Ado-抗性的半胱胺类似物和其用途
AU2016326397A1 (en) * 2015-09-22 2018-04-19 Viking Therapeutics, Inc. Conjoint therapies with inhibitors of glucose production
WO2017062363A1 (en) * 2015-10-05 2017-04-13 Joslin Diabetes Center Methods of use of betatrophin
CN106620715B (zh) * 2015-11-04 2021-04-06 江苏恒瑞医药股份有限公司 一种治疗糖尿病的药物组合物及其制备方法
WO2017087532A1 (en) 2015-11-16 2017-05-26 The Regents Of The University Of California Methods of treating non-alcoholic steatohepatitis (nash) using cysteamine compounds
US10143665B2 (en) 2015-11-17 2018-12-04 Horizon Orphan Llc Methods for storing cysteamine formulations and related methods of treatment
US10155948B2 (en) 2016-05-12 2018-12-18 Kangwon National University University-Industry Cooperation Foundation and Pharmaceutical composition for preventing or treating diabetic complications and screening method for preventive or therapeutic agent for diabetic complications
KR101881662B1 (ko) * 2016-05-12 2018-07-26 강원대학교산학협력단 당뇨성 합병증 예방 및 치료용 약제학적 조성물 및 당뇨성 합병증 예방 또는 치료제 스크리닝 방법
MX2019008847A (es) * 2017-01-25 2019-12-16 Adare Pharmaceuticals Inc Profarmacos de cisteamina.
CN109439553B (zh) * 2018-12-26 2020-08-21 华熙生物科技股份有限公司 产麦角硫因的菌株及其筛选方法
WO2025179209A1 (en) * 2024-02-22 2025-08-28 Whitehead Institute For Biomedical Research Methods and agents to study and restore suppressed protein mobility in disease

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4062950A (en) * 1973-09-22 1977-12-13 Bayer Aktiengesellschaft Amino sugar derivatives
DE3343141A1 (de) * 1983-11-29 1985-06-05 Hermann P.T. 7400 Tübingen Ammon Verwendung von cystein-derivaten oder deren salzen, zur steigerung der insulinsekretion der langerhans'schen inseln der bauchspeicheldruese
US5401880A (en) * 1987-06-04 1995-03-28 Oculon Corporation Chemical prevention or reversal of cataract by phase separation inhibitors
DE3883712T2 (de) * 1987-06-04 1993-12-16 Massachusetts Inst Technology Chemisches verhindern oder rückgängigmachen von star-erkrankungen durch phasentrennungsinhibitoren.
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US6746678B1 (en) 1991-02-22 2004-06-08 Howard K. Shapiro Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments
ZA949715B (en) 1993-12-14 1996-06-06 Lilly Co Eli Aqueous solution inclusion complexes of benzothiophene compounds with water soluble cyclodextrins and pharmaceutical formulations and methods thereof
FR2716625B1 (fr) 1994-02-25 1996-04-26 Gouchet Franck Arno Préparation et utilisation de formes pharmaceutiques et cosmétiques contenant des composés d'inclusion avec les cyclodextrines de cystéamine, sels de cystéamine, ou dérivés de la cystéamine, sous forme de sel ou non.
US5714519A (en) * 1995-06-07 1998-02-03 Ergo Science Incorporated Method for regulating glucose metabolism
KR100245077B1 (ko) * 1997-04-25 2000-02-15 김영환 반도체 메모리 소자의 딜레이 루프 럭크 회로
US6100736A (en) * 1997-06-05 2000-08-08 Cirrus Logic, Inc Frequency doubler using digital delay lock loop
FR2774591B1 (fr) * 1998-02-12 2000-05-05 Lipha Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie
US6621496B1 (en) * 1999-02-26 2003-09-16 Micron Technology, Inc. Dual mode DDR SDRAM/SGRAM
US6521266B1 (en) 1999-09-23 2003-02-18 Morris A. Mann Composition for growth hormone production and release, appetite suppression, and methods related thereto
EP1229918B1 (de) 1999-11-03 2008-03-26 Bristol-Myers Squibb Company Arzneimittel, umfassend eine kombination aus metformin und glibenclamide
US6630176B2 (en) 2000-03-07 2003-10-07 Mount Sinai School Of Medicine Of New York University Herbal remedies for treating allergies and asthma
WO2001082916A2 (en) * 2000-05-03 2001-11-08 Tularik Inc. Combination therapeutic compositions and methods of use
WO2001095944A2 (en) 2000-06-12 2001-12-20 Mills Randell L Photocleavable prodrugs for selective drug delivery
CN1144585C (zh) * 2000-12-13 2004-04-07 华扩达动物科学[I.P.2]有限公司 含有半胱胺或其盐类的促进动物快速生长的组合物及用途
JP3715529B2 (ja) 2000-12-19 2005-11-09 雅嗣 田中 アルコール代謝促進剤
US6746578B2 (en) * 2001-05-31 2004-06-08 International Business Machines Corporation Selective shield/material flow mechanism
JP2006508096A (ja) * 2002-11-07 2006-03-09 ディーエスエム アイピー アセッツ ビー．ブイ． 没食子酸エピガロカテキンを含む新規な栄養補助組成物
US8017651B2 (en) * 2002-11-22 2011-09-13 Bionexus, Ltd. Compositions and methods for the treatment of HIV-associated fat maldistribution and hyperlipidemia
WO2005049002A1 (en) 2003-11-19 2005-06-02 Omega Bio-Pharma International Ltd. Materials and methods for improving alcohol metabolism and alleviating the effects of hangovers
WO2005060342A2 (en) 2003-12-19 2005-07-07 Omega Bio-Pharma International Ltd. Cysteamine compounds for treating allergy
RU2367423C2 (ru) * 2003-12-19 2009-09-20 ОМЕГА БИО-ФАРМА (Ай.Пи. 3) ЛИМИТЕД Композиции и способы для лечения диабета
CN1976691B (zh) * 2004-05-03 2010-10-13 奥加生物药业(I.P.3)有限公司 半胱胺用于治疗高胆固醇血症和糖尿病并发症

Also Published As

Publication number Publication date
SG149814A1 (en) 2009-02-27
AR047779A1 (es) 2006-02-22
RU2006126062A (ru) 2008-01-27
US20090048154A1 (en) 2009-02-19
TWI350751B (en) 2011-10-21
KR20070004569A (ko) 2007-01-09
CA2549717C (en) 2012-11-13
IL176259A0 (en) 2006-10-05
MXPA06007100A (es) 2007-01-19
AU2004308934B2 (en) 2010-04-01
EP1696897A4 (de) 2008-12-10
IL176259A (en) 2016-02-29
US20050137125A1 (en) 2005-06-23
JP2007514771A (ja) 2007-06-07
HK1099507A1 (en) 2007-08-17
KR101329369B1 (ko) 2013-11-14
JP4845740B2 (ja) 2011-12-28
EP1696897A1 (de) 2006-09-06
AU2004308934A1 (en) 2005-07-14
RU2367423C2 (ru) 2009-09-20
CA2549717A1 (en) 2005-07-14
US7442720B2 (en) 2008-10-28
WO2005063226A1 (en) 2005-07-14
BRPI0417829A (pt) 2007-04-10
US8188151B2 (en) 2012-05-29
EP1696897B1 (de) 2011-07-06
MY143799A (en) 2011-07-15
TW200524583A (en) 2005-08-01
CN101897970A (zh) 2010-12-01

Similar Documents

Publication Publication Date Title
ATE515261T1 (de) Zusammensetzungen zur behandlung von diabetes
ATE494780T1 (de) 2-cyanobenzolsulfonamidverbindungen zur behandlung von samen
ATE435271T1 (de) Zusammensetzungen zur wäschebehandlung
ATE430187T1 (de) Zusammensetzungen zur wäschebehandlung
ATE410430T1 (de) 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose
DE602004028763D1 (de) Te zur behandlung von virenerkrankungen
DE602005007717D1 (de) Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen
ATE465742T1 (de) Tlr7-liganden zur behandlung von hepatitis c
EP1755661A4 (de) Verwendung von gelsolin zur behandlung von infektionen
ATE527241T1 (de) Pyridiazinonderivate zur behandlung von tumoren
ATE326842T1 (de) Zusammensetzung zur saatgutbehandlung
ATE429218T1 (de) Pinolensäure zur behandlung von übergewicht
DE602006017980D1 (de) 3,4-substituierte pyrrolidin-derivate zur behandlung von hypertonie
DE502005010499D1 (de) Implantat zur Behandlung von Fettsucht
DE602004022153D1 (de) Verbindungen zur behandlung von obesitas
DE602004022035D1 (de) Verwendung von pthalide derivativen zur behandlung
ATE493125T1 (de) Carbamatverbindungen zur behandlung von schmerz
DE602006017367D1 (de) Amino-oxo-indolyliden-verbindungen zur verwendung in der behandlung von juckender kopfhaut
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
ATE457725T1 (de) Kynurenine 3-hydroxylase inhibitoren zur behandlung von diabetes
DE602006003094D1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate zur behandlung von unfruchtbarkeit
DE602004026067D1 (de) Gerät zur Behandlung von Füßen
ATE378053T1 (de) Pharmazeutische zusammensetzungen zur behandlung von nierenfunktionsstörungen
ATE425269T1 (de) Zusammensetzung zur behandlung von leder
ATE482707T1 (de) 1-ä2h-1-benzopyran-2-on-8-ylü- piperazin- derivate zur behandlung von schmerzen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties